Abstract Background Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are myeloproliferative neoplasms (MPNs) characterized in most cases by a unique somatic mutation, JAK2 V617F. Recent studies revealed that JAK2 V617F occurs more frequently in a specific JAK2 haplotype, named JAK2 46/1 or GGCC haplotype, which is tagged by rs10974944 (C/G) and/or rs12343867 (T/C). This study examined the impact of single nucleotide polymorphisms (SNPs) of the JAK2 locus on MPNs in a Japanese population. Methods We sequenced 24 JAK2 SNPs in Japanese patients with PV. We then genotyped 138 MPN patients (33 PV, 96 ET, and 9 PMF) with known JAK2 mutational status and 107 controls for a novel SNP, in addition to two SNPs k...
JAK2V617F is an acquired mutation associated with polycythemia vera (PV), essential thrombocythemia ...
The association between somatic JAK2 mutation and myeloproliferative neoplasms (MPNs) is now well es...
The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The ...
Chronic myeloproliferative neoplasms (MPNs) are a group of related conditions characterized by the o...
This study aimed to verify the association between the JAK2 46/1 haplotype (V617F positive) and some...
Introduction: This study aimed to verify the association between the JAK2 46/1 haplotype (V617F posi...
The germline JAK2 haplotype known as “GGCC or 46/1 haplotype” (haplotypeGGCC_46/1) consists of a com...
The germline JAK2 haplotype known as “GGCC or 46/1 haplotype” (haplotypeGGCC_46/1) consists of a com...
2014-2015 > Academic research: refereed > Publication in refereed journalVersion of RecordPublishe
The 46/1 JAK2 haplotype predisposes to V617F-positive myeloproliferative neoplasms but the underlyin...
JAK2 (V617F) is associated with a genetic predisposition to its acquisition, as it is preferentially...
The 46/1 JAK2 haplotype predisposes to V617F-positive myeloproliferative neoplasms, but the underlyi...
Somatic gene V617F mutation in JAK2 is a critical molecular and biological indicator to diagnosis of...
Although the concept of somatic driver mutations in myeloproliferative neoplasms (MPNs) represented ...
BACKGROUND: Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are clonal my...
JAK2V617F is an acquired mutation associated with polycythemia vera (PV), essential thrombocythemia ...
The association between somatic JAK2 mutation and myeloproliferative neoplasms (MPNs) is now well es...
The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The ...
Chronic myeloproliferative neoplasms (MPNs) are a group of related conditions characterized by the o...
This study aimed to verify the association between the JAK2 46/1 haplotype (V617F positive) and some...
Introduction: This study aimed to verify the association between the JAK2 46/1 haplotype (V617F posi...
The germline JAK2 haplotype known as “GGCC or 46/1 haplotype” (haplotypeGGCC_46/1) consists of a com...
The germline JAK2 haplotype known as “GGCC or 46/1 haplotype” (haplotypeGGCC_46/1) consists of a com...
2014-2015 > Academic research: refereed > Publication in refereed journalVersion of RecordPublishe
The 46/1 JAK2 haplotype predisposes to V617F-positive myeloproliferative neoplasms but the underlyin...
JAK2 (V617F) is associated with a genetic predisposition to its acquisition, as it is preferentially...
The 46/1 JAK2 haplotype predisposes to V617F-positive myeloproliferative neoplasms, but the underlyi...
Somatic gene V617F mutation in JAK2 is a critical molecular and biological indicator to diagnosis of...
Although the concept of somatic driver mutations in myeloproliferative neoplasms (MPNs) represented ...
BACKGROUND: Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are clonal my...
JAK2V617F is an acquired mutation associated with polycythemia vera (PV), essential thrombocythemia ...
The association between somatic JAK2 mutation and myeloproliferative neoplasms (MPNs) is now well es...
The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood. The ...